NGNE Neurogene, Inc. Common Stock
XNAS
23.54
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NGNE
$23.54
—
Key stats
$23.54
- 52-Week Range
- $15.93 – $43.66
- YTD
- +16.77%
- IV Rank (30D)
- 16.73
- Straddle Price
- $5.35
- P/C Vol Ratio
- 0.33
- Market Cap
- $0.5B
- Open
- $23.75
- Day Range
- $23.32 – $24.43
- Volume
- 123,203
- Prev Close
- $23.55
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 2.39 |
| Cost of Equity (CAPM) | 18.13% (VRP-adj) |
| WACC | 18.29% |
| Volatility Risk Premium | +49.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -51.2% |
| Book / Price | 41.9% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $31.45 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $25.07 |
| Bollinger Width / SMA20 | 110.7% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: ALKS, BIIB, DNTH, NBIX, XENE
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
95%
20-Day Fair Value
≈ by Nov 25, 2026
$24.33
α +3.4%
rank 81%
conviction
99%
40-Day Fair Value
≈ by Dec 24, 2026
$24.67
α +4.8%
rank 82%
conviction
98%
60-Day Fair Value
≈ by Jan 22, 2027
$24.75
α +5.2%
rank 78%
conviction
95%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 44.4× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.1× · 3 peers |
| Peer P/B | $36.08 | 44% | median 3.7× · 5 peers |
| Peer P/S | n/a | 0% | median 4.3× · 4 peers |
| Market Anchor (SMA50) | $31.45 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $22.23 | 56% | 10 strikes · skew +0.35 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 131
- List Date
- 2023-12-19
- CIK
- 0001404644
- Next Earnings
- 2026-11-12 (Pre-Market)
- EPS Forecast
- ($1.49) (5 est.)
- Headquarters
- New York, NY
- Homepage
- https://www.neurogene.com
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy dev…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | 51.79% | -30.76% | -12.40% | 2.88% |
| Feb | -- | 1.01% | 5.05% | 28.15% | 11.40% |
| Mar | -- | 59.06% | -27.76% | -2.80% | 9.50% |
| Apr | -- | -26.29% | 55.36% | 20.45% | 16.51% |
| May | -- | 11.34% | 10.45% | 5.55% | 9.11% |
| Jun | -- | -2.26% | -15.77% | 14.20% | -1.28% |
| Jul | -- | 1.28% | 13.44% | -2.84% | 3.96% |
| Aug | -- | -7.63% | -15.15% | 10.25% | -4.18% |
| Sep | -- | 27.85% | -11.76% | -26.54% | -3.48% |
| Oct | -- | 10.19% | 90.60% | -11.34%* | 29.82% |
| Nov | -- | -44.80% | -32.13% | -- | -38.47% |
| Dec | 28.34% | -6.96% | 0.59% | -- | 7.32% |
| Total | 28.34% | 32.41% | -16.07% | 10.53% | 13.80% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $25.07
SMA 50: $31.45
SMA 200: $27.60
Current: $23.54
EMA 12: $24.61
EMA 26: $26.64
MACD: -2.0308 | Signal: 0.3020
BEARISH
ADX (14): 21.69
WEAK TREND
+DI: 21.50
−DI: 27.51
Momentum Oscillators
RSI (14): 37.56
NEUTRAL
Stoch %K: 31.93
Stoch %D: 40.91
Williams %R: -70.98
Volume & Volatility
BB Upper: $28.55
BB Lower: $21.60
NEUTRAL
OBV: -948,205
Vol SMA 20: 317,563
Vol ROC: -68.25%
ATR: $2.00
True Range: $1.11
HV 20: 77.5%
HV 30: 76.4%
HV 60: 66.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All NGNE news →
Earnings History
7 of 8 under expected move
Avg Expected Move
26.41%
Avg Actual Move
8.85%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-18 | Pre-Market | 26.87% | 42.58% | 1.58x | Exceeded |
| 2025-03-24 | Pre-Market | 37.12% | 1.76% | 0.05x | Within |
| 2025-05-09 | Pre-Market | 31.00% | 1.80% | 0.06x | Within |
| 2025-08-11 | Pre-Market | 18.50% | 4.10% | 0.22x | Within |
| 2025-11-13 | Pre-Market | 35.55% | 14.77% | 0.42x | Within |
| 2026-03-23 | Pre-Market | 27.30% | 1.63% | 0.06x | Within |
| 2026-05-12 | Pre-Market | 17.81% | 2.10% | 0.12x | Within |
| 2026-08-11 | Pre-Market | 17.10% | 2.05% | 0.12x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
NGNE Options Activity & IV Rank
NGNE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 88.2%
7-DTE IV: —
Expected Move: $5.35
7-DTE Move: $5.35
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 54
Put Volume: 18
P/C Volume: 0.333
BULLISH
Call OI: 116
Put OI: 18
P/C OI: 0.155
Total OI: 134
ATM Options Pricing
ATM Call: $2.90
ATM Put: $2.45
Call %: 12.3%
Put %: 10.4%
Chain Summary
Chain Volume: 312
Chain OI: 1,086
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 89th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
89%
vs own history
GEX tilt
+0.85
OI-weighted, today
Vanna tilt
+0.96
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +0.96: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 95.2% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)16.7LowOct 26
Straddle Price (30 DTE)$5.35Oct 26
Beta Analysis
Risk Metrics
Beta: 1.5084
Alpha: -14.25%
Correlation: 0.2493
R-Squared: 6.2%
Stock Volatility: 77.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NGNE
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $12.9M | #1412 of 6285 | +5.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $4.5M | #1013 of 1945 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.3M | #2786 of 3716 | -79.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $642K | #2506 of 3138 | -53.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $7K | #4133 of 4729 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NGNE Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 22,027,808 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$3.79M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.91M | 76.62% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $839.72K | 22.14% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $47.17K | 1.24% | 2026-06-30 |
3 filers$468.61K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $462.31K | 98.66% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $3.15K | 0.67% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $3.15K | 0.67% | 2026-06-30 |
NGNE Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Rachel McMinn | Chief Executive Officer | Exer (M) | +756 | $25.32 | $19.1K | EDGAR |
| 2026-07-07 | Christine Mikail Cvijic | President and CFO | Sell (S) | −4,800 | $36.12 | -$173.4K | EDGAR |
| 2026-07-02 | Christine Mikail Cvijic | President and CFO | Sell (S) | −4,800 | $34.71 | -$166.6K | EDGAR |
| 2026-06-16 | Keith Woods | Director | Grant (A) | +15,400 opt | — | EDGAR | |
| 2026-06-16 | Keith Woods | Director | Grant (A) | +12,050 opt | — | EDGAR | |
| 2026-06-16 | Keith Woods | Director | Grant (A) | +7,700 opt | — | EDGAR | |
| 2026-05-08 | Christine Mikail Cvijic | President and CFO | Sell (S) | −9,600 | $31.25 | -$300.0K | EDGAR |
| 2026-05-07 | Christina Shafer | Chief Commercial Officer | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-03-30 | Julie Jordan | Chief Medical Officer | Sell (S) | −828 | $21.89 | -$18.1K | EDGAR |
| 2026-03-30 | Rachel McMinn | Chief Executive Officer | Sell (S) | −3,352 | $22.07 | -$74.0K | EDGAR |
| 2026-03-30 | Christine Mikail Cvijic | President and CFO | Sell (S) | −2,558 | $21.62 | -$55.3K | EDGAR |
| 2026-03-17 | Stuart Cobb | Chief Scientific Officer | Sell (S) | −6,797 | $20.81 | -$141.4K | EDGAR |
| 2026-03-17 | Christine Mikail Cvijic | President and CFO | Sell (S) | −4,045 | $20.81 | -$84.2K | EDGAR |
| 2026-03-03 | Christine Mikail Cvijic | President and CFO | Sell (S) | −4,800 | $25.11 | -$120.5K | EDGAR |
| 2026-02-24 | Stuart Cobb | Chief Scientific Officer | Award (A) | +16,500 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NGNE Insider Holdings
5 insiders · @ $23.54
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Samsara BioCapital, L.P. | 10%+ Owner | 1,717,127 | $40.42M | $3.78M | 1 | 2024-11-27 |
| 2 | Rachel McMinn | Chief Executive Officer | 1,345,063 | $31.66M | $895.0K | 6 | 2026-10-02 |
| 3 | Christine Mikail Cvijic | President and CFO | 88,240 | $2.08M | -$484.9K | 11 | 2026-07-07 |
| 4 | Stuart Cobb | Chief Scientific Officer | 33,303 | $784.0K | -$244.4K | 5 | 2026-03-17 |
| 5 | Julie Jordan | Chief Medical Officer | 12,472 | $293.6K | -$18.1K | 4 | 2026-03-30 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NGNE Board & Officers
As of SEC filings through Oct 2, 2026Directors 8
- Sarah B. Noonberg · since Aug 8, 2019
- Rohan Palekar · since Mar 2, 2022
- Cory S. Freedland · since Dec 18, 2023
- Rachel McMinn · since Dec 18, 2023
- Robert Baffi · since Dec 18, 2023
- Robert Keith Woods · since Dec 18, 2023
- Keith Woods · on file since Feb 2026
- Christine Mikail Cvijic · listed since May 2026
Officers 5
- Rachel McMinn · Chief Executive Officer · since Dec 18, 2023
- Christine Mikail Cvijic · President and CFO · since Dec 18, 2023
- Stuart Cobb · Chief Scientific Officer · since Dec 18, 2023
- Julie Jordan · Chief Medical Officer · since Jan 16, 2024
- Christina Shafer · Chief Commercial Officer · since Apr 20, 2026
Changes in the last 10 years (72)
| May 8, 2026 | Christine Mikail Cvijic first listed as a director in an SEC filing |
| Apr 20, 2026 | Christina Shafer became Chief Commercial Officer |
| Feb 24, 2026 | Keith Woods first on file as a director |
| Nov 25, 2024 | Srinivas Akkaraju became a 10% owner |
| Nov 25, 2024 | Samsara BioCapital, L.P. became a 10% owner |
| Nov 25, 2024 | Samsara BioCapital GP, LLC became a 10% owner |
| Jan 16, 2024 | Julie Jordan became Chief Medical Officer |
| Dec 18, 2023 | Stuart Cobb became Chief Scientific Officer |
| Dec 18, 2023 | Robert Keith Woods became a director |
| Dec 18, 2023 | Robert Baffi became a director |
| Dec 18, 2023 | Rachel McMinn became a director |
| Dec 18, 2023 | Rachel McMinn became Chief Executive Officer |
| Dec 18, 2023 | Julian Baker left the board, per their own SEC filing |
| Dec 18, 2023 | Julian Baker is no longer a 10% owner, per their own SEC filing |
| Dec 18, 2023 | Felix Baker left the board, per their own SEC filing |
| Dec 18, 2023 | Felix Baker is no longer a 10% owner, per their own SEC filing |
| Dec 18, 2023 | Cory S. Freedland became a director |
| Dec 18, 2023 | Christine Mikail Cvijic became President and CFO |
| Dec 18, 2023 | Baker Brothers Life Sciences LP left the board, per their own SEC filing |
| Dec 18, 2023 | Baker Brothers Life Sciences LP is no longer a 10% owner, per their own SEC filing |
| Dec 18, 2023 | Baker Bros. Advisors LP left the board, per their own SEC filing |
| Dec 18, 2023 | Baker Bros. Advisors LP is no longer a 10% owner, per their own SEC filing |
| Dec 18, 2023 | Baker Bros. Advisors (GP) LLC left the board, per their own SEC filing |
| Dec 18, 2023 | Baker Bros. Advisors (GP) LLC is no longer a 10% owner, per their own SEC filing |
| Dec 18, 2023 | 667, L.p. left the board, per their own SEC filing |
| Dec 18, 2023 | 667, L.p. is no longer a 10% owner, per their own SEC filing |
| Dec 13, 2023 | The company announced the departure of Todd E Simpson from the board in an SEC filing |
| Dec 13, 2023 | The company announced the departure of Martin Babler from the board in an SEC filing |
| Aug 17, 2023 | Julian Baker first listed as a 10% owner in an SEC filing |
| Aug 17, 2023 | Felix Baker first listed as a 10% owner in an SEC filing |
| Aug 17, 2023 | Baker Brothers Life Sciences LP first listed as a 10% owner in an SEC filing |
| Aug 17, 2023 | Baker Bros. Advisors LP first listed as a 10% owner in an SEC filing |
| Aug 17, 2023 | Baker Bros. Advisors (GP) LLC first listed as a 10% owner in an SEC filing |
| Aug 17, 2023 | 667, L.p. first listed as a 10% owner in an SEC filing |
| Apr 4, 2023 | Priti Patel reported in an SEC filing no longer being Chief Medical Officer |
| Mar 6, 2023 | The company announced the departure of Jonathan G Drachman from the board in an SEC filing |
| Mar 6, 2023 | The company announced the departure of Jonathan G Drachman as President and CEO in an SEC filing |
| May 16, 2022 | Erin Lavelle first on file as a director |
| Mar 14, 2022 | Donna Cochener became General Counsel, SVP Legal |
| Mar 2, 2022 | Sean Michael Smith became Principal Accounting Officer |
| Mar 2, 2022 | Rohan Palekar became a director |
| Feb 25, 2022 | The company announced the departure of Lewis T Williams from the board in an SEC filing |
| Feb 14, 2022 | The company announced the departure of Robert Ho as Chief Financial Officer in an SEC filing |
| Nov 17, 2021 | The company announced the departure of Holly Vance as General Counsel in an SEC filing |
| Apr 30, 2021 | Priti Patel became Chief Medical Officer |
| Jan 30, 2021 | Carl Walkey became Senior Vice President |
| Oct 19, 2020 | Holly Vance became General Counsel |
| Sep 8, 2020 | Martin Babler became a director |
| Jun 1, 2020 | Erin M. Lavelle became a director |
| Mar 26, 2020 | Redmile Group, LLC became a 10% owner |
| Mar 26, 2020 | Jeremy Green became a 10% owner |
| Mar 16, 2020 | Robert Ho became Chief Financial Officer |
| Dec 20, 2019 | Julian Baker no longer listed as a 10% owner in SEC filings |
| Dec 20, 2019 | Felix Baker no longer listed as a 10% owner in SEC filings |
| Dec 20, 2019 | Baker Brothers Life Sciences LP no longer listed as a 10% owner in SEC filings |
| Dec 20, 2019 | Baker Bros. Advisors LP no longer listed as a 10% owner in SEC filings |
| Dec 20, 2019 | Baker Bros. Advisors (GP) LLC no longer listed as a 10% owner in SEC filings |
| Dec 20, 2019 | 667, L.p. no longer listed as a 10% owner in SEC filings |
| Aug 8, 2019 | Sarah B. Noonberg became a director |
| Aug 8, 2019 | Meta Cantey Boyd became a director |
| Aug 8, 2019 | Lewis T Williams became a director |
| Aug 8, 2019 | Jonathan G Drachman became a director |
| Aug 8, 2019 | Jonathan G Drachman became President and CEO |
| Mar 13, 2018 | Lloyd MacKenzie listed as Chief Operating Officer (previously VP Technical Operations) in SEC filings |
| May 9, 2017 | Julian Baker first listed as a director in an SEC filing |
| May 9, 2017 | Felix Baker first listed as a director in an SEC filing |
| May 9, 2017 | Baker Brothers Life Sciences LP first listed as a director in an SEC filing |
| May 9, 2017 | Baker Bros. Advisors LP first listed as a director in an SEC filing |
| May 9, 2017 | Baker Bros. Advisors (GP) LLC first listed as a director in an SEC filing |
| May 9, 2017 | 667, L.p. first listed as a director in an SEC filing |
| Mar 23, 2017 | Richard S Levy became a director |
| Mar 23, 2017 | Kelvin Neu became a director |
Not reported recently (24)
- Srinivas Akkaraju · Last reported as a 10% owner in an SEC filing dated Nov 27, 2024
- Samsara BioCapital, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 27, 2024
- Samsara BioCapital GP, LLC · Last reported as a 10% owner in an SEC filing dated Nov 27, 2024
- Sean Michael Smith · Last reported as Principal Accounting Officer in an SEC filing dated Aug 14, 2023
- Erin Lavelle · Last reported as a director in an SEC filing dated Jun 9, 2023
- Meta Cantey Boyd · Last reported as a director in an SEC filing dated Jun 8, 2023
- Carl Walkey · Last reported as Senior Vice President in an SEC filing dated Aug 4, 2022
- Donna Cochener · Last reported as General Counsel, SVP Legal in an SEC filing dated Aug 4, 2022
- Erin M. Lavelle · Last reported as a director in an SEC filing dated May 13, 2021
- Sean P. Nolan · Last reported as a director in an SEC filing dated May 7, 2020
- Jeremy Green · Last reported as a 10% owner in an SEC filing dated Apr 6, 2020
- Redmile Group, LLC · Last reported as a 10% owner in an SEC filing dated Apr 6, 2020
- Lloyd MacKenzie · Last reported as Chief Operating Officer in an SEC filing dated Aug 9, 2018
- David Main · Last reported as a director in an SEC filing dated Aug 9, 2018
- Kamran Alam · Last reported as CFO, Vice President Finance in an SEC filing dated Aug 9, 2018
- Shelley McCloskey · Last reported as VP, HR and Administration in an SEC filing dated Aug 9, 2018
- Daniel J Levitt · Last reported as a director in an SEC filing dated May 16, 2018
- Gary Bridger · Last reported as a director in an SEC filing dated May 9, 2018
- Robert Pelzer · Last reported as a director in an SEC filing dated May 9, 2018
- Abigail Jenkins · Last reported as Chief Commercial Officer in an SEC filing dated Mar 13, 2018
- Barbara Troupin · Last reported as Chief Medical Officer in an SEC filing dated Mar 13, 2018
- Kelvin Neu · Last reported as a director in an SEC filing dated Mar 27, 2017
- Richard S Levy · Last reported as a director in an SEC filing dated Mar 27, 2017
- David Chilton Mitchell · Last reported as VP Global Regulatory & Quality in an SEC filing dated Mar 10, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
NGNE Proposed Insider Sales (Form 144)
Latest: 2026-05-06
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Christine Cvijic | Officer | 14,400 | $416.7K | 2026-05-06 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-03-13 | STUART COBB | Officer | 6,797 | $151.6K | 2026-03-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-27 | Christine Cvijic | Officer | 9,600 | $188.9K | 2026-02-27 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2025-05-14 | STUART COBB | Officer | 6,797 | $105.4K | 2025-05-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-03-07 | MARTIN BABLER | Director | 2,500 | $98.2K | 2024-03-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-03-04 | SEAN SMITH | Officer | 371 | $13.6K | 2024-03-04 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-02-09 | TODD SIMPSON | Director | 2,500 | $77.5K | 2024-02-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-02-06 | ERIN LAVELLE | Director | 2,500 | $76.1K | 2024-02-06 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
36 ETFs hold NGNE
25 shown · $53.58M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $14.5M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $9.2M | $74.6B | 2026-10-23 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.06% | $6.7M | $10.4B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $4.9M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $3.4M | $13.9B | 2026-10-23 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.03% | $2.9M | $10.7B | 2026-10-23 |
| 7 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.04% | $2.6M | $6.6B | 2026-10-23 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.5M | — | 2026-09-30 |
| 9 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.09% | $1.1M | $1.2B | 2026-10-23 |
| 10 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $878,250 | — | 2026-09-30 |
| 11 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.04% | $830,844 | — | 2026-10-23 |
| 12 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $693,288 | $3.2B | 2026-10-23 |
| 13 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $501,686 | — | 2026-10-23 |
| 14 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.28% | $452,533 | — | 2026-05-31 |
| 15 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.03% | $404,280 | — | 2026-09-30 |
| 16 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.76% | $351,298 | — | 2026-07-31 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $323,695 | — | 2026-10-23 |
| 18 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $268,399 | — | 2026-10-23 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.05% | $260,110 | — | 2026-10-26 |
| 20 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $254,411 | — | 2026-10-23 |
| 21 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $178,504 | — | 2026-10-26 |
| 22 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $129,737 | — | 2026-10-23 |
| 23 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $107,058 | $20.4B | 2026-10-23 |
| 24 | DFAU Dimensional US Core Equity Market ETF | Dimensional | 0.00% | $73,923 | $13.0B | 2026-10-23 |
| 25 | HELX Franklin Genomic Advancements ETF | Franklin | 0.15% | $53,271 | $34.7M | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-5.03
TTM Revenue
—
TTM Net Income
$-111.11M
TTM Op. Cash Flow
$-86.82M
Quarterly figures (11 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-34.49M | $-1.53 | $-23.76M |
| Q1 '26 | 2026-03-31 | — | $-30.93M | $-1.39 | $-26.12M |
| Q4 '25 | 2025-12-31 | — | $-24.73M | $-1.13 | $-17.43M |
| Q3 '25 | 2025-09-30 | — | $-20.95M | $-0.99 | $-19.51M |
| Q2 '25 | 2025-06-30 | — | $-22.02M | $-1.05 | $-19.46M |
| Q1 '25 | 2025-03-31 | — | $-22.65M | $-1.08 | $-20.77M |
| Q4 '24 | 2024-12-31 | $0.00 | $-19.51M | $-0.99 | $-17.50M |
| Q3 '24 | 2024-09-30 | — | $-20.22M | $-1.19 | $-15.56M |
| Q2 '24 | 2024-06-30 | $925.00K | $-18.49M | $-1.09 | $-15.89M |
| Q1 '24 | 2024-03-31 | — | $-16.92M | $-1.00 | $-21.65M |
| Q4 '23 | 2023-12-31 | — | $2.38M | $48.10 | $-16.97M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.39
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-51.2%
ROA
-45.5%
Div Yield
0.00%
FCF Yield
-16.74%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$518.53M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.97M
SI % of Float
38.64%
Days to Cover
11.73
Short Vol Ratio
51.7%
Free Float
12.87M
Float %
64.3%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14